TCRT Alaunos Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1107421 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.0%
TTM net income YoY10.0%
TTM EPS YoY39.1%
Revenue 3-yr CAGR-41.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-121,033.3%
Net margin-120,766.7%
FCF margin—
EBITDA margin-119,966.7%
Returns
ROE-192.0%
ROA-128.4%
ROIC (approx.)-469.9%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets49.4%
Debt / equity0.00x
Current ratio1.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-46.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5,000 | $10,000 |
| R&D expense | $1.36M | $362,000 |
| SG&A expense | $2.87M | $4.46M |
| Operating income | -$4.22M | -$4.81M |
| Interest expense | — | $0 |
| Income tax | $0 | — |
| Net income | -$4.18M | -$4.68M |
| EBITDA | -$4.22M | -$4.81M |
| EPS (basic) | -2.20 | -2.92 |
| EPS (diluted) | -2.20 | -2.92 |
| Weighted avg. shares (diluted) | 1.95M | 1.60M |
| Balance sheet | ||
| Cash & equivalents | $1.39M | $1.09M |
| Receivables | $3,000 | $5,000 |
| Current assets | $1.99M | $2.75M |
| PP&E, net | $91,000 | $0 |
| Total assets | $2.97M | $2.75M |
| Current liabilities | $813,000 | $692,000 |
| Long-term debt | — | $0 |
| Total debt | — | $0 |
| Total liabilities | $813,000 | $692,000 |
| Shareholders' equity | $2.15M | $2.06M |
| Net debt | — | -$1.09M |
| Shares outstanding | 2.35M | 1.60M |
| Cash flow statement | ||
| Operating cash flow | -$2.87M | -$4.97M |
| Capital expenditure | $98,000 | $0 |
| Free cash flow | -$2.97M | -$4.97M |
| Investing cash flow | -$98,000 | $0 |
| Financing cash flow | $3.26M | $0 |
| Depreciation & amortization | $7,000 | $2,000 |
| Stock-based compensation | $796,000 | $435,000 |
Free plan shows the latest 2 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.